LC-MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501)
スポンサーリンク
概要
- 論文の詳細を見る
- 2006-08-07
著者
-
BUHROW Sarah
Department of Oncology, Division of Developmental Oncology Research, Mayo Clinic and Foundation
-
REID Joel
Department of Oncology, Division of Developmental Oncology Research, Mayo Clinic and Foundation
-
JIA Lee
DTP/DCTD/NCI
-
MCGOVERN Renee
Department of Oncology, Division of Developmental Oncology Research, Mayo Clinic and Foundation
-
COVEY Joseph
DTP/DCTD/NCI
-
KOBS Dean
Battelle
-
GROSSI Irma
Battelle
-
AMES Matthew
Department of Oncology, Division of Developmental Oncology Research, Mayo Clinic and Foundation
-
Reid Joel
Department Of Oncology Division Of Developmental Oncology Research Mayo Clinic And Foundation
-
Buhrow Sarah
Department Of Oncology Division Of Developmental Oncology Research Mayo Clinic And Foundation
-
Ames Matthew
Department Of Oncology Division Of Developmental Oncology Research Mayo Clinic And Foundation
-
Mcgovern Renee
Department Of Oncology Division Of Developmental Oncology Research Mayo Clinic And Foundation
関連論文
- LC-MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501)
- Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of halofuginone in plasma
- Validated high-performance liquid chromatographic assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydroxymethyl-3-methyl-1-triazeno) imidazole-4-carboxamide and 5-(3-methyl-1-triazeno) imidazole-4-carboxamide